Epidemiological Characteristics and Risk Factors Related to Drug-resistant Tuberculosis in Luanda, Angola.
Journal
The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507
Informations de publication
Date de publication:
10 01 2022
10 01 2022
Historique:
received:
10
06
2021
accepted:
16
11
2021
pubmed:
11
1
2022
medline:
26
4
2022
entrez:
10
1
2022
Statut:
epublish
Résumé
Tuberculosis (TB) is a major cause of illness and public health concern, especially in resource-limited countries. This study analyzed the characteristics related to anti-TB drug resistance. Moreover, we examined the evidence-based indications for the treatment of active TB in Angola. This study evaluated the medical records of 176 patients screened for TB from January to September 2016 in Luanda, the capital city of Angola. Approximately 66.5% of the patients were newly diagnosed with active TB. The residence area showed a significant relationship with TB (P = 0.025), whereas age group (P = 0.272), gender (P = 0.853), and HIV status (P = 0.284) did not showed any relationship with TB. Overall, 72.4% of TB patients had resistance to at least one of the anti-TB drugs. The risk of anti-TB drug resistance was higher in males (odds ratio [OR]: 1.22; 95% confidence interval [CI]: 0.42-3.58, P = 0.685] and in TB-HIV coinfected patients [OR: 1.39; (95% CI: 0.26-7.28), P = 0.700], whereas it was lower in patients aged 30 years or older (OR: 0.56; 95% CI: 0.18-1.69) P = 0.303) and in patients living in urbanized areas (OR: 0.74; 95% CI: 0.17-3.25; P = 0.685). Our findings showed that drug-resistant TB is emerging in Angola. Further studies on factors related to anti-TB drug resistance are urgently needed to ascertain the magnitude of the problem and to proffer strategies toward TB control in Angola.
Identifiants
pubmed: 35008058
doi: 10.4269/ajtmh.21-0659
pmc: PMC8922512
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
779-784Références
FEMS Microbiol Rev. 2017 May 1;41(3):354-373
pubmed: 28369307
J Pak Med Assoc. 2016 Aug;66(8):989-93
pubmed: 27524534
PLoS One. 2017 Sep 25;12(9):e0185105
pubmed: 28945771
Lancet Respir Med. 2018 Apr;6(4):299-314
pubmed: 29595511
Int J Tuberc Lung Dis. 2017 Apr 1;21(4):446-451
pubmed: 28284261
Int J Tuberc Lung Dis. 2009 Jan;13(1):68-73
pubmed: 19105881
Dtsch Arztebl Int. 2019 Oct 25;116(43):729-735
pubmed: 31755407
J Infect Dis. 2017 Nov 3;216(suppl_6):S629-S635
pubmed: 29112747
Antimicrob Resist Infect Control. 2016 Aug 31;5(1):30
pubmed: 27583136
Int J Tuberc Lung Dis. 2019 Jan 1;23(1):67-72
pubmed: 30674377
Microbiol Spectr. 2014 Jun;2(3):
pubmed: 26103975
PLoS One. 2017 Jul 13;12(7):e0180996
pubmed: 28704459
Can J Infect Dis Med Microbiol. 2017;2017:3276240
pubmed: 28713434
Mem Inst Oswaldo Cruz. 2012 Sep;107(6):760-6
pubmed: 22990966
BMC Public Health. 2018 Sep 12;18(1):1114
pubmed: 30208864
BMC Infect Dis. 2017 May 31;17(1):379
pubmed: 28569148
BMC Infect Dis. 2017 Aug 22;17(1):579
pubmed: 28830384
Lancet Infect Dis. 2016 Apr;16(4):473-9
pubmed: 26725446
J Public Health (Oxf). 2018 Dec 1;40(4):820-826
pubmed: 29186489
BMC Public Health. 2015 Jun 20;15:572
pubmed: 26092570
Rev Saude Publica. 2017 Apr 27;51(0):41
pubmed: 28489185
J Bras Pneumol. 2020 Nov 18;46(5):e20200015
pubmed: 33237130
J Natl Med Assoc. 2007 Oct;99(10):1185-9
pubmed: 17987922
Emerg Top Life Sci. 2020 Dec 11;4(4):423-436
pubmed: 33258943
Nat Rev Microbiol. 2012 May 14;10(6):407-16
pubmed: 22580364
Afr J Lab Med. 2018 Dec 06;7(2):805
pubmed: 30568903
Int J Infect Dis. 2017 Mar;56:14-20
pubmed: 28163165
Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S18-S19
pubmed: 28043540